Lexicon Pharmaceuticals, Inc. (LXRX) earnings
LXRX earnings moved a median of +0.86% by the close. Quarterly and annual LXRX reports and results, each read against the price at its own news timestamp. Back to the LXRX overview →
33 measured LXRX earnings events.
Where these LXRX earnings landedvs 33 measured LXRX earnings reactions
| Middle 50% of LXRX earnings reactions | -4.27% to +4.27% |
|---|---|
| Median reaction (to close) | +0.86% |
| Measured reactions | 33 |
Point-in-time · zero look-ahead
Half of the 33 LXRX earnings events with a measured close landed between -4.27% and +4.27%; 55% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q LEXICON PHARMACEUTICALS, For: Jun 30 | SEC filing · Form 10-Q | -4.75% | +2.07% | |
| Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates | Press release | +19.58% | +20.41% | |
| Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026 | Press release | +1.08% | +0.86% | |
| Form 10-Q LEXICON PHARMACEUTICALS, For: Mar 31 | SEC filing · Form 10-Q | +1.18% | +18.34% | |
| Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates | Press release | -4.85% | +1.82% | |
| Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 | Press release | +2.21% | +1.90% | |
| Form 10-K LEXICON PHARMACEUTICALS, For: Dec 31 | SEC filing · Form 10-K | +0.52% | +4.27% | |
| Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates | Press release | -3.25% | +6.49% | |
| Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026 | Press release | -0.34% | +1.35% | |
| Form 10-Q LEXICON PHARMACEUTICALS, For: Sep 30 | SEC filing · Form 10-Q | +0.75% | -10.71% | |
| Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates | Press release | +1.79% | +2.14% | |
| Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 | Press release | -1.49% | +0.00% | |
| Form 10-Q LEXICON PHARMACEUTICALS, For: Jun 30 | SEC filing · Form 10-Q | +4.19% | -4.27% | |
| Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates | Press release | +4.91% | +2.68% | |
| Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 | Press release | +1.24% | +0.00% | |
| Form 10-Q LEXICON PHARMACEUTICALS, For: Mar 31 | SEC filing · Form 10-Q | -5.86% | -8.29% | |
| Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates | Press release | -5.86% | -8.29% | |
| Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 | Press release | -1.39% | -8.90% | |
| Form 10-K LEXICON PHARMACEUTICALS, For: Dec 31 | SEC filing · Form 10-K | +1.50% | -1.47% | |
| Form 10-Q LEXICON PHARMACEUTICALS, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -7.63% | |
| Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update | Press release | +0.00% | -7.63% | |
| Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024 | Press release | -5.08% | +0.85% | |
| Form 10-Q LEXICON PHARMACEUTICALS, For: Jun 30 | SEC filing · Form 10-Q | +3.53% | -0.29% | |
| Lexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update | Press release | +3.53% | -0.29% | |
| Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024 | Press release | -0.83% | +7.37% | |
| Form 10-Q LEXICON PHARMACEUTICALS, For: Mar 31 | SEC filing · Form 10-Q | +10.31% | +4.82% | |
| Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update | Press release | +10.31% | +4.82% | |
| Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024 | Press release | +4.04% | -3.11% | |
| Form 10-K LEXICON PHARMACEUTICALS, For: Dec 31 | SEC filing · Form 10-K | +1.19% | -5.71% | |
| Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update | Press release | +7.76% | +21.12% | |
| Form 10-Q LEXICON PHARMACEUTICALS, For: Sep 30 | SEC filing · Form 10-Q | +0.44% | -8.41% | |
| Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update | Press release | -0.45% | +1.79% | |
| Lexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023 | Press release | +3.60% | +6.47% |
Keep exploring
More LXRX: analyst actions → · SEC filings → · LXRX overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Cidara Therapeutics, Inc. (CDTX) | 339 | +0.06% | 52% |
| DaVita Inc. (DVA) | 339 | +0.07% | 53% |
| Cellect Biotechnology Ltd. - American Depositary Shares (APOP) | 337 | -0.42% | 35% |
| Cardinal Health, Inc. (CAH) | 335 | +0.02% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.